<DOC>
	<DOCNO>NCT02512692</DOCNO>
	<brief_summary>The purpose study determine safety maximum tolerate dose ( MTD ) 90 Y TARE ( Y90 ) combination gemcitabine cisplatin patient unresectable intrahepatic cholangiocarcinoma ( ICC ) .</brief_summary>
	<brief_title>90Y Transarterial Radioembolization ( TARE ) Plus Gemcitabine Cisplatin Unresectable Intrahepatic Cholangiocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologic Documentation : Core needle biopsy surgical specimen confirm intrahepatic cholangiocarcinoma ( ICC ) . Patients must determine unresectable multidisciplinary team include hepatobiliary surgeon . No prior liver radiation therapy immunotherapy cholangiocarcinoma . Only previous single agent chemotherapy ICC allow . Patient may prior liver resection . Age &gt; 18 year age . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 ( see Appendix E ) Child 's Pugh score A ( see Appendix F ) Life expectancy great 4 month Normal organ marrow function outline protocol . Willingness use effective contraceptive method study . Patient may participate female ( female partner male subject ) , either childbearing potential ( define postmenopausal &gt; 1 year surgically sterile ) practice two form contraception . Sexually active male participant must agree use physical barrier method ( male latex rubber condom without spermicide ) . Patients well control HIV infection eligible CD4 count &gt; 499/cu mm viral load &lt; 50 copies/ml . Precertification 90Y TARE perform prior enrollment study . All patient must inform investigational nature study must ability understand willingness sign write informed consent document . Patients major surgery within 4 week prior enter study recover complication surgery 4 week earlier . Patients may receive investigational agent . Patients must grade III/IV cardiac disease define New York Heart Association ( NYHA ) Criteria Patients must NOT liver disease cirrhosis sever hepatic impairment define ChildPugh Class B C Pregnant woman exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>intrahepatic cholangiocarcinoma</keyword>
	<keyword>cholangiocarcinoma</keyword>
	<keyword>90Y TARE</keyword>
	<keyword>radioembolization</keyword>
	<keyword>gemcitabine cisplatin</keyword>
</DOC>